Apremilast Safety and PK Study in Recalcitrant Plaque Psoriasis

PHASE2CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

August 1, 2007

Primary Completion Date

April 1, 2009

Study Completion Date

May 1, 2009

Conditions
Psoriasis-Type PsoriasisPlaque-Type Psoriasis
Interventions
DRUG

Apremilast

20 mg PO (by mouth) twice per day (BID) for 84 days and then an additional 84 days during the optional treatment extension period. For subjects meeting the dose escalation criteria, dosage during the optional treatment extension period can be increased to 30 mg BID.

Trial Locations (4)

63117

Central Dermatology, St Louis

97223

Oregon Medical Research Center, P.C., Portland

02111

Tufts-New England Medical Center Hospitals, Boston

75246-1613

Baylor Research Institute, Dallas

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Amgen

INDUSTRY